Treatment with Nuplazid (pimavanserin) can ease symptoms of Parkinson’s disease psychosis (PDP) for up to 10 weeks, and is generally safe and well-tolerated, according to new clinical trial data. The findings were published in Parkinsonism and Related Disorders, in the study, “Efficacy results of pimavanserin…
Treatment with a low dose of the immune-modulating medication sargramostim was well-tolerated and eased motor symptoms in a small clinical trial of people with Parkinson’s disease. The results “provide the basis for larger scale assessments to determine clinical efficacy of a reduced sargramostim regimen within the [Parkinson’s] population,” according…
Limitations in functional abilities due to advanced Parkinson’s disease result in billions of dollars of lost economic value in the U.S., but effective treatments that restore some essential abilities can lessen this lost value, a study reports. Levodopa-carbidopa intestinal gel, sold in the U.S. under the brand name…
Non-motor symptoms are major determinants of quality of life (QOL) for people with Parkinson’s disease who have undergone deep brain stimulation, known as DBS, a new study reports. “Postoperative QOL was associated with non-motor symptoms … rather than motor symptoms,” the researchers found, specifically noting that patients with…
A new formulation of rasagiline, approved for Parkinson’s disease, may allow the therapy to be given by applying it to the skin. The treatment’s new formulation was described in the European Journal of Pharmaceutics and Biopharmaceutics, in a study titled “Microemulsion-based gel for the…
People with moderate or advanced Parkinson’s disease have abnormally low levels of caffeine in their saliva, despite normal caffeine metabolism, a new study indicates. The findings suggest that measuring caffeine in saliva could be useful for gauging Parkinson’s disease progression. The study, “Salivary caffeine in Parkinson’s…
Scientists have identified genetic variations that are associated with different rates of disease progression in people with Parkinson’s disease. The findings suggest that the genetic changes that affect disease progression are distinct from those that impact whether a person will get Parkinson’s at all, and that disease initiation and…
The Michael J. Fox Foundation (MJFF) is hosting its second virtual walk event this weekend, and for the first time a three-day effort spanning May 7–9, to raise money to support research for Parkinson’s disease. Registration for the Virtual 5K/10K/Half Marathon is available online. Runners and walkers…
Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. The investigational medication SEP-363856 might ease symptoms of Parkinson’s disease psychosis, according to data from a…
Dopamine-releasing cells in the brain, much like most other hormone-producing cells, have a self-regulating feedback mechanism that controls their activity, researchers have discovered. That is, healthy nerve cells themselves determine how much dopamine will be released, the research team found, in contrast with the prevailing view that nearby cells “control”…
Get regular updates to your inbox.